Ipamorelin: A Ghrelin-Receptor Agonist, Not a GHRH Analogue

Ipamorelin is a pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH2. PubChem resolves it as CID 9831659, formula C38H49N9O5, molecular weight 711.9 g/mol, CAS 170851-70-4. In the Novo Nordisk literature it appears as NNC 26-0161.

Three of the five residues are not standard proteinogenic amino acids. Position 1 is α-aminoisobutyric acid, a doubly methylated glycine that constrains backbone conformation and resists aminopeptidase attack. Positions 3 and 4 are D-configured - D-2-naphthylalanine and D-phenylalanine - presenting the wrong stereochemistry to proteases that expect L-amino acids. This is why a five-residue peptide is stable enough to be useful; an all-L pentapeptide would not survive circulation.

It is worth registering how small this molecule is relative to the others on the growth axis. Tesamorelin is 44 residues and over 5,100 daltons. Modified GRF (1-29) is 29 residues. Ipamorelin is five residues and 712 daltons - closer in size to a small molecule than to a peptide hormone. That is a consequence of engaging a different receptor with a different pharmacophore requirement.

This is the single most important thing to understand about ipamorelin, and the point most often lost when it is grouped with GHRH analogues. Tesamorelin and both CJC-1295 variants bind the GHRH receptor. Ipamorelin binds GHS-R1a, the growth hormone secretagogue receptor - a distinct class A G-protein-coupled receptor with its own gene, its own expression pattern across pituitary and hypothalamus, and its own endogenous ligand.

The history here is genuinely odd. Howard and colleagues cloned GHS-R in 1996 as an orphan receptor: they knew synthetic secretagogues acted on it, but no natural ligand was known. Ipamorelin was published two years later, still against an orphan target. Only in 1999 did Kojima and colleagues identify ghrelin, an acylated peptide from the stomach, as the endogenous ligand. The class was therefore developed backwards - the drugs preceded the hormone they mimic.

That sequence explains features of the literature that otherwise look incidental. Because ghrelin signalling spans appetite regulation and gastrointestinal motility as well as growth hormone release, GHS-R1a agonists have effects across all three, and the clinical development of ipamorelin ultimately followed the motility arm rather than the endocrine one. Signalling through GHS-R1a proceeds mainly via Gq and phospholipase C, mobilising intracellular calcium in somatotrophs - mechanistically distinct from the Gs/cAMP route the GHRH receptor uses. The two pathways converge on growth hormone release from different directions, which is the stated rationale behind blends pairing a GHRH-receptor agonist with a secretagogue.

The word carries specific technical content, and it refers to selectivity across pituitary axes rather than across receptors. Earlier synthetic secretagogues - GHRP-6, GHRP-2, hexarelin - did release growth hormone, but not only growth hormone. Arvat and colleagues quantified this in humans in 1997: GHRP-2 and hexarelin raised prolactin, ACTH and cortisol alongside growth hormone, with a direct comparison against GHRH, TRH and CRH as reference stimuli.

A compound that engages the somatotroph and the corticotroph together is a blunter research tool and a harder clinical proposition, because any observed effect becomes difficult to attribute to growth hormone rather than to glucocorticoid or prolactin changes. Raun and colleagues' claim for ipamorelin was that it released growth hormone with potency comparable to the earlier peptides while leaving ACTH and cortisol substantially unaffected - hence the title, 'the first selective growth hormone secretagogue'.

Two caveats belong with that claim. It was established in the original characterisation work rather than reproduced across many independent human studies, so its robustness rests largely on one research programme. And selectivity across pituitary axes says nothing about the non-endocrine arms of GHS-R1a biology - appetite signalling and gastrointestinal motility remain part of the receptor's function, and the compound's own clinical development history is evidence that those effects are real.

Ipamorelin's controlled human evidence consists of one randomised Phase 2 proof-of-concept trial, published by Beck and colleagues in 2014, in patients undergoing bowel resection. The indication was postoperative ileus - the motility arm of ghrelin-receptor biology, not the growth hormone arm. It followed the receptor's gastrointestinal function rather than its endocrine function, and it did not lead to an approved indication.

The remainder is preclinical, and it is worth being specific about what that literature contains rather than gesturing at it. Rodent studies have examined ipamorelin against glucocorticoid-associated reductions in bone formation, somatotroph responsiveness after chronic administration in young rats, nitrogen balance under steroid conditions, and gastrointestinal transit in ileus models. These are useful mechanistic reports. None of them is human evidence, and none establishes an outcome in people.

So the honest position on ipamorelin is narrower than its reputation. The receptor pharmacology is well characterised and the selectivity claim is specific and testable. What is absent is any completed human programme showing that engaging GHS-R1a selectively produces a durable outcome worth having. That gap is not unusual for peptides in this catalogue, but it should be stated rather than filled by inference from the rodent work.

Against tesamorelin, the contrast is stark in both directions. Tesamorelin acts on a different receptor, has two completed Phase 3 trials, and holds an approved indication. Ipamorelin acts on GHS-R1a, has one Phase 2 study in an unrelated indication, and holds none. Anything that presents them as alternative routes to the same result is glossing over both the receptor difference and a very large difference in scrutiny.

Against the CJC-1295 pair, the comparison is about pathway rather than pharmacokinetics. The DAC-versus-non-DAC question is a question about how long a single receptor is occupied. Ipamorelin is not on that axis at all - swapping it for a GHRH analogue changes which receptor is engaged, not for how long. The convergence happens downstream, at growth hormone release from the somatotroph.

Against IGF-1 LR3, the distance is greatest. Ipamorelin acts upstream of the pituitary and leaves the entire endogenous axis and its feedback loops intact. IGF-1 LR3 is an analogue of the axis's terminal effector, engineered specifically to evade the binding proteins that normally regulate it. One works through the system; the other works around it.